Results 211 to 220 of about 86,323 (286)

The PARPscore system using poly (ADP-ribose) polymerase (PARP) family features and tumor immune microenvironment in glioma. [PDF]

Discov Oncol
Zhang C, Feng J, Zhou X, Zhang J, Tao C, Zhou H.   +5 more
europepmc   +1 more source

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells. [PDF]

Biomedicines
Zhou D, Liu W, Zhang Y, Li C.
europepmc   +1 more source

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions. [PDF]

Biomolecules
Bondar D, Karpichev Y.
europepmc   +1 more source

Excessive exercise elicits poly (ADP-ribose) Polymerase-1 activation and global protein PARylation driving muscle dysfunction and performance impairment. [PDF]

Mol Metab
Crisol BM, Rocha MB, Franco B, Morelli AP, Katashima CK, Junior SJA, Carneiro FS, Braga RR, Brícola RS, de Azambuja G, Costa RG, Esteves AM, Mori MA, Oliveira MCG, Cintra DE, Pauli JR, Larsen FJ, da Silva ASR, Ropelle ER.   +18 more
europepmc   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo. [PDF]

BMC Cancer
Sekine Y, Oka D, Ohtsu A, Nakayama H, Miyao T, Miyazawa Y, Arai S, Koike H, Matsui H, Shibata Y, Suzuki K.   +10 more
europepmc   +1 more source

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development. [PDF]

Pharmaceutics
Pöstyéni E, Gábriel R, Kovács-Valasek A.   +2 more
europepmc   +1 more source

Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications. [PDF]

JCO Precis Oncol
Torrado C, Plummer R, Yap TA.
europepmc   +1 more source

Imaging poly(ADP-ribose) polymerase-1 (PARP1) <i>in vivo</i> with ¹⁸F-labeled brain penetrant positron emission tomography (PET) ligand. [PDF]

Acta Pharm Sin B
Zhou X, Chen J, Patel JS, Ran W, Li Y, Van RS, Ibrahim MMH, Zhao C, Gao Y, Rong J, Chaudhary AF, Li G, Hu J, Davenport AT, Daunais JB, Shao Y, Ran C, Collier TL, Haider A, Schuster DM, Levey AI, Wang L, Corfas G, Liang SH.   +23 more
europepmc   +1 more source